

TERCICA INC  
Form 8-K  
July 19, 2006

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 18, 2006**

---

**TERCICA, INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**

(State or other jurisdiction of incorporation)

**000-50461**  
(Commission File Number)

**26-0042539**  
(IRS Employer Identification No.)

**2000 Sierra Point Parkway, Suite 400**

**Brisbane, CA 94005**

(Address of principal executive offices, including Zip Code)

**Registrant's telephone number, including area code: (650) 624-4900**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Edgar Filing: TERCICA INC - Form 8-K

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - x Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

On July 18, 2006, Tercica, Inc. (the Company ) and Ipsen, S.A. ( Ipsen ) issued a joint press release announcing that the Company and Ipsen have agreed to a worldwide strategic collaboration in endocrinology. A copy of the joint press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d)

| Exhibit | Exhibit Title |
|---------|---------------|
|---------|---------------|

|      |                                                                                                           |
|------|-----------------------------------------------------------------------------------------------------------|
| 99.1 | Press Release entitled Ipsen and Tercica To Enter into Worldwide Strategic Collaboration in Endocrinology |
|------|-----------------------------------------------------------------------------------------------------------|

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Tercica, Inc.**

(Registrant)

By: /s/ STEPHEN N. ROSENFELD  
Stephen N. Rosenfield  
*Executive Vice President of Legal Affairs*

Dated: July 18, 2006

**Item 9.01. Financial Statements and Exhibits.**

**(d)**

| <b>Exhibit</b> | <b>Exhibit Title</b> |
|----------------|----------------------|
|----------------|----------------------|

|      |                                                                                                           |
|------|-----------------------------------------------------------------------------------------------------------|
| 99.1 | Press Release entitled Ipsen and Tercica to Enter into Worldwide Strategic Collaboration in Endocrinology |
|------|-----------------------------------------------------------------------------------------------------------|